https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-01 / Adv. Immunol. 2006;90:243-95
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-01 / Adv. Immunol. 2006;90:243-952006-01-01 00:00:002019-02-15 09:19:49Immunity to melanoma antigens: from self-tolerance to immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-01 / Biol. Pharm. Bull. 2006 Jan;29(1):100-4
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-01 / Biol. Pharm. Bull. 2006 Jan;29(1):100-42006-01-01 00:00:002019-02-15 09:19:53Vaccine efficacy of fusogenic liposomes containing tumor cell-lysate against murine B16BL6 melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-12-06 / Cancer Immunol. Immunother. 2006 Oct;55(10):1209-18
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-12-06 / Cancer Immunol. Immunother. 2006 Oct;55(10):1209-182005-12-06 00:00:002019-02-15 09:19:47Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-12-01 / Clin. Exp. Immunol. 2005 Dec;142(3):555-68
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-12-01 / Clin. Exp. Immunol. 2005 Dec;142(3):555-682005-12-01 00:00:002019-02-15 08:49:34Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-11-29 / Cancer Immunol. Immunother. 2006 Oct;55(10):1238-46
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-11-29 / Cancer Immunol. Immunother. 2006 Oct;55(10):1238-462005-11-29 00:00:002019-02-15 09:19:48Induction of anti-tumor immunity by vaccination with dendritic cells pulsed with anti-CD44 IgG opsonized tumor cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-11-26 / Cancer Immunol. Immunother. 2006 Aug;55(8):1011-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-11-26 / Cancer Immunol. Immunother. 2006 Aug;55(8):1011-62005-11-26 00:00:002019-02-15 09:19:50Lentiviral vector expression of tumour antigens in dendritic cells as an immunotherapeutic strategy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-11-01 / Anticancer Res. 2005 Nov-Dec;25(6A):3741-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-11-01 / Anticancer Res. 2005 Nov-Dec;25(6A):3741-62005-11-01 00:00:002019-02-15 09:19:54Combined immunocell therapy using activated lymphocytes and monocyte-derived dendritic cells for malignant melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-11-01 / Clin. Cancer Res. 2005 Nov;11(21):7692-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-11-01 / Clin. Cancer Res. 2005 Nov;11(21):7692-92005-11-01 00:00:002019-02-15 09:19:56Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-09-27 / Cancer Immunol Immunother 2006 Jul;55(7):819-29
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-09-27 / Cancer Immunol Immunother 2006 Jul;55(7):819-292005-09-27 00:00:002005-09-27 00:00:00Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-09-01 / J. Immunother. 2005 Sep-Oct;28(5):505-16
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-09-01 / J. Immunother. 2005 Sep-Oct;28(5):505-162005-09-01 00:00:002019-02-15 09:19:57Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon
